A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : anti-PD-1 / anti-programmed cell death protein 1

[Related PubMed/MEDLINE]
Total Number of Papers: 47
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   anti-PD-1  (>> Co-occurring Abbreviation)
Long Form:   anti-programmed cell death protein 1
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A new role for circulating T follicular helper cells in humoral response to anti-PD-1 therapy. cTfh, NSCLC, qRT-PCR, TLS
2020 Allele Frequency-Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. AF, anti-PD-L1, bTMB, CI, HR, NCC, ORR, OS, PFS
2020 Cascade of reactive oxygen species generation by polyprodrug for combinational photodynamic therapy. CA, PA, ROS
2020 Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer. AI, NSCLC, PS
2020 Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. ---
2020 Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. CPI, MM, TILs
2020 Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. irAEs
2020 Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients? PD-L1
2020 In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma. CM, ICIs, MAPKis, PEAs, PFS
10  2020 Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies. ---
11  2020 Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher. EGFR
12  2020 Multipanel mass cytometry reveals anti-PD-1 therapy-mediated B and T cell compartment remodeling in tumor-draining lymph nodes. TDLNs
13  2020 Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment. CVV, ICB, OVT, TILs, TME
14  2020 Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay. IHC, PD-L1
15  2020 Radio-Immunotherapy: A Case Report of 'Abscopal Hyper-Progression'? ---
16  2020 Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor: A case report and literature review. CR, ESCC, ICI, MSI, PD-L1, PR, TIL, TMB
17  2020 The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. COX, NSAIDs, ORRs, OS, PFS
18  2020 The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. anti-CTLA-4, anti-PD-L1, FDA, ICIs, TILs
19  2019 Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. CR, HLA
20  2019 Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. CI, irTD, NSCLC, NSq, OR, TSH, TTF-1
21  2019 Current opinions in immune checkpoint inhibitors rechallenge in solid cancers. Anti-CTLA4, anti-PDL1, ICI
22  2019 Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. anti-PD-L1, HCC
23  2019 Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising? anti-PD-L1, CPIs
24  2019 Intestinal microbiota predicts lung cancer patients at risk of immune-related diarrhea. D-F
25  2019 Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. IRE, PDAC
26  2019 Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma. ICI, irAE
27  2019 Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. irAEs, NSCLC, PFS
28  2019 Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy. ---
29  2019 Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. anti-CTLA-4, CI, HRs, ICIs, OS-HRs, RCTs
30  2019 Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact? CI
31  2019 Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. SCCHN
32  2019 The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. COX, NSAIDs, ORRs, OS, PFS
33  2018 Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma. AJCC, ECOG, LDH
34  2018 Dramatic response to nivolumab in xeroderma pigmentosum skin tumor. XP
35  2018 Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. PDX, TNBC
36  2018 Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. AEs, CTCAE
37  2018 TIM-3, a promising target for cancer immunotherapy. anti-CTLA-4, TIM-3
38  2018 Uveal Effusion After Immune Checkpoint Inhibitor Therapy. anti-PD-L1
39  2017 Immunotherapy for Lung Malignancies: From Gene Sequencing to Novel Therapies. anti-PDL-1
40  2017 Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. DAMP, FACS, GBM, MV, PD-L1
41  2017 Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. ---
42  2017 Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. CTLA-4
43  2017 Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. CI, HR, ORs, PFS
44  2016 Adjuvant ipilimumab in stage III melanoma: New landscape, new questions. DMFS, OS, RFS
45  2016 Biomarkers for immunotherapy in genitourinary malignancies. anti-CTLA4
46  2016 Immunotherapy for Gastroesophageal Cancer. anti-CTLA4
47  2016 Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. anti-CTLA-4, BrMets, SRS